M.E. Nuttall
Department of Bone and Cartilage Biology
SmithKline Beecham Pharmaceuticals
King of Prussia
Pennsylvania 19406
USA
Name/email consistency: high
- Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents. Nuttall, M.E., Pendrak, I., Emery, J.G., Nadeau, D.P., Fisher, P.W., Nicholson, T.A., Zhu, Y., Suva, L.J., Kingsbury, W.D., Gowen, M. Cancer Chemother. Pharmacol. (2001)
- Drug discovery and target validation. Nuttall, M.E. Cells. Tissues. Organs. (Print) (2001)
- Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?. Nuttall, M.E., Gimble, J.M. Bone (2000)
- Inhibition of caspase-3-like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro. Nuttall, M.E., Nadeau, D.P., Fisher, P.W., Wang, F., Keller, P.M., DeWolf, W.E., Goldring, M.B., Badger, A.M., Lee, D., Levy, M.A., Gowen, M., Lark, M.W. J. Orthop. Res. (2000)
- Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells. Nuttall, M.E., Stroup, G.B., Fisher, P.W., Nadeau, D.P., Gowen, M., Suva, L.J. Am. J. Physiol., Cell Physiol. (2000)
- The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro. Nuttall, M.E., Fisher, P.W., Suva, L.J., Gowen, M. Eur. J. Cancer (2000)
- Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. Nuttall, M.E., Patton, A.J., Olivera, D.L., Nadeau, D.P., Gowen, M. J. Bone Miner. Res. (1998)
- Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Nuttall, M.E., Bradbeer, J.N., Stroup, G.B., Nadeau, D.P., Hoffman, S.J., Zhao, H., Rehm, S., Gowen, M. Endocrinology (1998)
